Drug Profile
Research programme: hearing loss therapeutics - Otonomy
Alternative Names: OTO 5XX; Sensorineural therapeutics - OtonomyLatest Information Update: 02 May 2023
Price :
$50
*
At a glance
- Originator Otonomy; University of California
- Developer Otonomy
- Class Small molecules
- Mechanism of Action Neurotransmitter stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hearing loss